These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20942304)

  • 1. [Efficacy and tolerability of pantoprazole in the treatment of gastroesophageal reflux disease].
    Gillessen A
    MMW Fortschr Med; 2010 Apr; 152 Suppl 1():21-9. PubMed ID: 20942304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.
    Haag S; Holtmann G
    Clin Ther; 2010 Apr; 32(4):678-90. PubMed ID: 20435237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study.
    Remes-Troche JM; Sobrino-Cossío S; Soto-Pérez JC; Teramoto-Matsubara O; Morales-Arámbula M; Orozco-Gamiz A; Tamayo de la Cuesta JL; Mateos G
    Clin Drug Investig; 2014 Feb; 34(2):83-93. PubMed ID: 24347282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D; Paré P; Pericak D; Pyzyk M;
    Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study.
    Körner T; Schütze K; van Leendert RJ; Fumagalli I; Costa Neves B; Bohuschke M; Gatz G
    Digestion; 2003; 67(1-2):6-13. PubMed ID: 12743434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis.
    Kindt S; Imschoot J; Tack J
    Dis Esophagus; 2011 Nov; 24(8):531-7. PubMed ID: 21418126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease.
    Pai VG; Pai NV; Thacker HP; Shinde JK; Mandora VP; Erram SS
    World J Gastroenterol; 2006 Oct; 12(37):6017-20. PubMed ID: 17009401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian Intravenous Pantoprazole Study Group.
    Wurzer H; Schutze K; Bethke T; Fischer R; Luhmann R; Riesenhuber C
    Hepatogastroenterology; 1999; 46(27):1809-15. PubMed ID: 10430350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
    van Zyl J; van Rensburg C; Vieweg W; Fischer R
    Digestion; 2004; 70(1):61-9. PubMed ID: 15297779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease.
    Scholten T; Teutsch I; Bohuschke M; Gatz G
    Clin Drug Investig; 2007; 27(4):287-96. PubMed ID: 17358101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pantoprazole on duodeno-gastro-esophageal reflux (DGER).
    Kunsch S; Neesse A; Linhart T; Steinkamp M; Fensterer H; Adler G; Gress TM; Ellenrieder V
    Z Gastroenterol; 2009 Mar; 47(3):277-82. PubMed ID: 19280541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term management of GERD in the elderly with pantoprazole.
    Calabrese C; Fabbri A; Di Febo G
    Clin Interv Aging; 2007; 2(1):85-92. PubMed ID: 18044079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexlansoprazole for the treatment of esophagitis and GERD.
    Davies SL
    Drugs Today (Barc); 2010 Feb; 46(2):75-80. PubMed ID: 20393635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Financial restrictions in health care systems could affect treatment quality of GERD-patients].
    Gillessen A; Schöffel L; Naumburger A
    Z Gastroenterol; 2006 May; 44(5):379-85. PubMed ID: 16688654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study.
    Goh KL; Benamouzig R; Sander P; Schwan T;
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):205-11. PubMed ID: 17301646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
    Hongo M; Miwa H; Kusano M;
    J Gastroenterol Hepatol; 2012 May; 27(5):913-8. PubMed ID: 22142515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease.
    Mönnikes H; Heading RC; Schmitt H; Doerfler H
    World J Gastroenterol; 2011 Jul; 17(27):3235-41. PubMed ID: 21912473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Panum (pantoprazole) effectiveness in the treatment of patients with GERD].
    Masharova AA; Ianova OB; Valitova ÉR; Kim VA; Zelenkin SA
    Eksp Klin Gastroenterol; 2011; (4):81-5. PubMed ID: 21916207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD).
    Tsou VM; Baker R; Book L; Hammo AH; Soffer EF; Wang W; Comer GM;
    Clin Pediatr (Phila); 2006 Oct; 45(8):741-9. PubMed ID: 16968960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.